Vivoryon Therapeutics N.V. (0R3M.L)

0.6370 -0.1230 (-16.18%) At close: 02:18PM BST

Vivoryon Therapeutics N.V.

Weinbergweg 22
Halle 06120
Germany
49 345 555 9900
https://www.vivoryon.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Schaeffer Ph.D.	Chief Business Officer, Member of the Management Board & Executive Director	315k	N/A	1969
Mr. Frank T. Weber M.D.	Chairman of the Management Board, CEO, Chief Medical Officer & Executive Director	N/A	N/A	1960
Dr. Manuela Bader	Director of Investor Relations & Communications	N/A	N/A	N/A
Dr. Konrad Glund	Co-Founder & Advisor	222.11k	N/A	1953
Dr. Hendrik Liebers	Advisor	319.2k	N/A	1971

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

Corporate governance

Vivoryon Therapeutics N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.